<DOC>
	<DOCNO>NCT01787279</DOCNO>
	<brief_summary>This expand access programme make Pegasys ( peginterferon alfa-2a ) available patient HBeAg-negative chronic hepatitis B Morocco . Patients receive Pegasys 180 mcg subcutaneously weekly 48 week efficacy safety record treatment 24 week follow-up .</brief_summary>
	<brief_title>An Expanded Access Study Pegasys ( Peginterferon Alfa-2a ) Patients With HBeAg-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 &lt; /= 70 year age HBeAgnegative chronic hepatitis B HBsAgpositive least 6 month , anti hepatitis B ( HBs ) negative Serum alanine transaminase ( ALT ) &gt; 2 ULN ( upper limit normal ) &lt; /= 10 x Upper limit normal ( ULN ) Hepatitis B virus ( HBV ) DNA &gt; 10'000 copies/ml ( Roche Monitor Taqman ) No previous treatment interferon ( standard pegylated ) nucleoside analogue Women childbearing potential must agree use reliable contraception study 3 month treatment completion Previous antiviral interferonbased therapy chronic hepatitis B Pregnant lactate woman Evidence decompensated liver disease Coinfection active hepatitis A , hepatitis C , hepatitis D and/or human immunodeficiency virus ( HIV ) History evidence medical condition associate chronic liver disease viral hepatitis Previous current hepatocellular carcinoma History evidence bleed oesophageal varix condition consistent decompensated liver disease Inadequate hematologic renal function Serum bilirubin level &gt; 2 time upper limit normal Severe psychiatric disease History severe seizure disorder current anticonvulsant use History evidence disease condition would make patient , opinion investigator , unsuitable study Evidence drug abuse within one year study entry Alcohol intake 3 standard drink per day men 2 standard drink per day woman ( 1 standard drink contain 10 g alcohol ) Participation another trial receipt investigational drug within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>